• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

CGM vs SMBG in Primary Care: What Does the T2D Evidence Say?


Patients with T2D see significant improvement in glycemic control using continuous glucose monitoring. MOBILE study lead author Thomas W. Martens, MD, highlights the evidence.

Use of continuous glucose monitoring (CGM) by patients with type 2 diabetes (T2D) treated in primary care settings improved glycemic control and improved time in target glucose range compared to standard blood glucose monitoring (BGM), according to results from the MOBILE study.

The MOBILE study is the first to investigate the efficacy of CGM vs traditional BGM on glycemic outcomes in patients with T2D who receive only daily basal insulin and other antihyperglycemic agents and do not administer prandial, or mealtime, insulin.

Lead author Thomas W. Martens, MD, recently spoke with Patient Care® Online about the study and the results. He prefaced those details with highlights of the evidence for use self monitoring of blood glucose (SMBG) and of the pivotal studies for use of advanced CGM in patients with T2D using multiple daily injections of insulin--all through his lens as a primary care provider.

Thomas W. Martens, MD, is a director at the Park Nicollet International Diabetes Center, an affiliate of Health Partners Institute in Minneapolis, Minnesota.

For additional interviews with Dr Martens on the MOBILE study, please see:

Tom Martens, MD, Talks about the Vision for CGM as Part of Primary Care for Type 2 Diabetes

Thomas W. Martens, MD: MOBILE Study Findings on CGM vs BGM in T2 Diabetes

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.